



# Blood Cadmium Levels and Incident Cardiovascular Events during Follow-up in a Population-Based Cohort of Swedish Adults: The Malmö Diet and Cancer Study

Lars Barregard, Gerd Sallsten, Björn Fagerberg, Yan Borné, Margaretha Persson, Bo Hedblad, and Gunnar Engström

<http://dx.doi.org/10.1289/ehp.1509735>

Received: 18 January 2015

Accepted: 20 October 2015

Advance Publication: 30 October 2015

**Note to readers with disabilities:** *EHP* will provide a [508-conformant](#) version of this article upon final publication. If you require a 508-conformant version before then, please contact [ehp508@niehs.nih.gov](mailto:ehp508@niehs.nih.gov). Our staff will work with you to assess and meet your accessibility needs within 3 working days.



National Institute of  
Environmental Health Sciences

# **Blood Cadmium Levels and Incident Cardiovascular Events during Follow-up in a Population-Based Cohort of Swedish Adults: The Malmö Diet and Cancer Study**

Lars Barregard<sup>1</sup>, Gerd Sallsten<sup>1</sup>, Björn Fagerberg<sup>2</sup>, Yan Borné<sup>3</sup>, Margaretha Persson<sup>3</sup>, Bo Hedblad<sup>3</sup>, and Gunnar Engström<sup>3</sup>

<sup>1</sup>Occupational and Environmental Medicine, Sahlgrenska University Hospital and University of Gothenburg, P.B. 414, SE 405 30 Gothenburg, Sweden; <sup>2</sup>Department of Molecular and Clinical Medicine, Wallenberg Laboratory for Cardiovascular and Metabolic Research, University of Gothenburg, and Sahlgrenska University Hospital, SE 413 45 Gothenburg, Sweden;

<sup>3</sup>Cardiovascular Epidemiology, Department of Clinical Sciences in Malmö, CRC, Jan Waldenströms Gata 35, Lund University and Skåne University Hospital, Malmö, 205 02 Malmö, Sweden

**Address correspondence to** Lars Barregard, P.B 414, SE 405 30 Gothenburg, Sweden.

Telephone: +46 31 734 299383. E-mail [lars.barregard@amm.gu.se](mailto:lars.barregard@amm.gu.se)

**Running title:** Cadmium and incident cardiovascular events

**Acknowledgments:** We thank Eva M Andersson for analysing the model with the effect of B-Cd represented using a smooth function (Supplemental Material Figure S2), and Niklas Forsgard for the cadmium analyses.

**Funding:** This study was supported by the Swedish Research Council, the Swedish Heart–Lung Foundation, the Swedish governmental research council FORTE, Sahlgrenska University

Hospital, and Malmö University Hospital. No funding source was involved in any part of this study, or the decision to submit the manuscript for publication.

**Competing financial interests:** Gunnar Engström has received personal fees from AstraZeneca R&D (as former employee) outside the submitted work. The other authors declare they have no actual or potential competing financial interest.

## Abstract

**Background:** Cadmium exposure may increase the risk of cardiovascular disease. The only published longitudinal study on cadmium and incident cardiovascular disease was performed in American Indians with relatively high cadmium exposure.

**Objectives:** Our aim was to examine the association between blood cadmium at baseline and incident cardiovascular events in a population-based study of Swedish men and women with cadmium levels similar to most European and US populations.

**Methods:** A Swedish population-based cohort (N= 6103, age 46 – 67 years) was recruited between 1991 and 1994. After excluding those with missing data on smoking, 4,819 participants remained. Acute coronary events, other major cardiac events, stroke, and cardiovascular mortality were followed until 2010. Associations with blood cadmium (estimated from cadmium in erythrocytes) were analyzed using Cox proportional hazards regression including potential confounders and important cardiovascular risk factors.

**Results:** Hazard ratios for all cardiovascular endpoints were consistently increased for participants in the 4th blood cadmium quartile (median 0.99 µg/L). In models which also included gender, smoking, waist circumference, education, physical activity, alcohol intake, serum triglycerides, HbA1c, and C-reactive protein, the hazard ratios comparing the highest and lowest quartiles of exposure were 1.8 (95% CI: 1.2, 2.7) for acute coronary events, and 1.9 (1.3, 2.9) for stroke. Hazard ratios in never-smokers were consistent with these estimates.

**Conclusions:** Blood cadmium in the highest quartile was associated with incident cardiovascular disease and mortality in our population-based samples of Swedish adults. The consistent results among never-smokers are important, since smoking is a strong confounder. Our findings suggest

that measures to reduce cadmium exposures are warranted, even in populations without unusual sources of exposure.

## Introduction

Exposure to the toxic metal cadmium (Cd) has adverse health effects at occupational or high-level environmental exposure. The most well-known toxic effects are kidney damage and osteoporosis/osteomalacia (Åkesson et al. 2014; Nordberg et al. 2015). In addition, cadmium is carcinogenic (IARC; Norberg et al. 2015). Cadmium contamination of agricultural soil is high in many countries, and exposure in non-smoking populations occurs via foods such as rice, wheat, vegetables, and potatoes (WHO 2011). Tobacco smoking further increases cadmium exposure; cadmium in tobacco smoke is effectively absorbed in the lungs. The majority of circulating cadmium is bound in erythrocytes. Cadmium in blood (B-Cd) and/or urine (U-Cd) is widely used for biological monitoring (Nordberg et al. 2015; WHO 2011).

Cadmium is cytotoxic, and experimental studies indicate that cadmium exposure may cause atherosclerosis (Almenara et al. 2013; Knoflach et al. 2011; Messner et al. 2009). A systematic review and meta-analysis summarized a number of epidemiological studies on environmental exposure to cadmium and cardiovascular disease (Tellez-Plaza et al. 2013b). The pooled estimate indicated that cardiovascular disease was 36% more likely in the highest exposure category compared with the lowest. Five cohorts had examined cardiovascular mortality prospectively (Li et al. 2011; Menke et al. 2011; Nawrot et al. 2008; Tellez-Plaza et al. 2012, 2013a). The only study on incident cardiovascular disease (including non-fatal disease) was the Strong Heart Study performed in American Indians (Tellez-Plaza et al. 2013a), which showed hazard ratios of 1.33 (95% CI 1.05, 1.68) for coronary heart disease and 1.87 (95% CI 1.22, 2.86) for stroke in the highest quartile of U-Cd (median 1.95  $\mu\text{g/g}$  creatinine) compared with the lowest (median 0.44  $\mu\text{g/g}$ ). The exposure was, however, much higher than what is typical in the US and Europe

(Tellez-Plaza et al. 2012; Akerstrom et al. 2013a). The review mentioned above concluded that there is evidence supporting cadmium as an independent risk factor for cardiovascular disease, but studies on incident disease are needed (Tellez-Plaza et al. 2013b).

The aim of the present study was to examine if cadmium exposure at baseline was associated with incident cardiovascular disease during 17 years of follow-up of a population-based study of Swedish men and women with blood cadmium levels typical for most European and US populations.

## **Methods**

### **Study population**

As previously described, all men and women age 45 – 64 years, in the city of Malmö, Sweden were invited to participate in the Malmö Diet and Cancer Study, investigating the relation between dietary factors and cancer (Berglund et al. 1993). Between 1991 and 1994, a random selection of half of those included in the Malmö Diet and Cancer Study, and born between 1926 and 1945, were invited to a cardiovascular substudy; almost all agreed to participate (Hedblad et al. 2000). In total, 6103 participants were included in the cardiovascular subcohort, and 5540 of them provided fasting blood samples. The present study includes participants (N=4819) with data available on cadmium in blood and on smoking (Supplemental Material, Figure S1). The study was approved by the regional ethics review board in Lund, Sweden. All participants provided written informed consent.

## **Cardiovascular risk factors at baseline**

The participants completed questionnaires concerning lifestyle (including smoking), socioeconomic status, health, and medication (Hedblad et al. 2000). They were categorized into never-smokers, ex-smokers, and current smokers. Pack-years of smoking were calculated from years of smoking and the number of cigarettes smoked daily for 3938 participants, including 95% of current smokers (1,208 of 1,276), 50% of ex-smokers (815 of 1,628), and all never-smokers (n=1915). Leisure time physical activity was defined as low if a participant fell in the lowest quartile of a composite measure of leisure time activities (Li et al. 2009). Low educational level was defined as less than 9 years of education. Height, waist circumference, and body mass were recorded. Systolic and diastolic blood pressure were measured after supine resting for 10 minutes.

Overnight fasting blood samples were drawn according to standard procedures at Malmö University Hospital for determination of HDL cholesterol, LDL cholesterol, triglycerides, hemoglobin A1c (HbA1c), and whole blood glucose. High sensitivity C-reactive protein (CRP) was measured from frozen samples (-80°C). Participants were classified as having diabetes mellitus if they reported the diagnosis in the questionnaire, used anti-diabetic medication, or had a fasting venous whole blood glucose  $\geq 6.1$  mmol/L.

## **Endpoints**

Outcomes were based on the International Classification of Diseases (ICD9 or ICD10) obtained from the Swedish National Hospital Discharge Register and Cause-of-Death Register, the Malmö Stroke Register, and the Swedish Coronary Angiography and Angioplasty Registry. These



registries have previously been described and validated (Hammar et al. 2001; Kahn et al. 2004; Ludvigsson et al. 2011; Sarno et al. 2013). The endpoints were:

1. Acute coronary event, defined as incident acute myocardial infarction (ICD9: 410, ICD 10: I21) or death (only) due to ischemic heart disease (ICD9: 412 or 414, ICD10: I22, I23, or I25).
2. Major adverse coronary event, including acute coronary event, coronary artery bypass graft (CABG), and percutaneous coronary intervention (PCI). CABG and PCI were identified from national registries.
3. Stroke (ICD9: 430, 431, 434, 436, ICD10: I60, I61, I63–I64).
4. Ischemic stroke (ICD9: 434, ICD10: I63).
5. Cardiovascular mortality (ICD9: 390–459, ICD10: I00–I99).
6. All-cause mortality (secondary endpoint).

The first four endpoints on the list above include both non-fatal and fatal events. For a specific outcome, we considered only the first event. Participants with an event before baseline were excluded in the analysis of this specific outcome. A participant could, however, contribute different events, for example first an AMI and later a stroke, or first a CABG and then an AMI. We could ascertain vital status for all participants except for 30 who emigrated during the observation period (data obtained from Statistics Sweden, based on the unique personal identification number).

## **Blood cadmium concentrations**

Both B-Cd and U-Cd reflect long term (many years) cumulative exposure and body burden, although B-Cd is also affected by recent exposure (Nordberg et al. 2015). Blood cadmium is located in erythrocytes, and levels in plasma are marginal (Nordberg et al. 2015). Cadmium was analyzed in erythrocytes (Ery-Cd) which had been obtained by centrifugation (1350 g) of whole blood collected in heparin tubes, and then kept frozen in cryotubes (NUNC) at -80°C since baseline. Cadmium in whole blood (B-Cd) was estimated by multiplying Ery-Cd by hematocrit, disregarding the minimum Cd concentration in plasma. The reason for using B-Cd as the primary Cd exposure biomarker was that most previous studies reported levels of cadmium in blood, not erythrocytes. The analysis was performed by inductively coupled plasma mass spectrometry operating in the helium collision cell mode as described previously (Fagerberg et al. 2015). The imprecision was 9.6% (coefficient of variation), as calculated for 50 duplicate samples. The limit of detection was 0.02 µg/L; no samples had levels below this. Analysis of external quality control samples and an interlaboratory comparison showed satisfactory results (Fagerberg et al. 2015).

## **Data analyses**

We studied outcomes in relation to baseline B-Cd until an event, emigration (N=30), or 31 December 2010, whichever came first. Since possible effects of cadmium might not be linear, we classified B-Cd in quartiles. We assessed differences between the 4<sup>th</sup> and 1<sup>st</sup> B-Cd quartiles for baseline characteristics using a t-test or the Wilcoxon rank sum test. We analysed associations between incident cardiovascular disease and baseline B-Cd analyzed using Cox proportional

hazards regression with age as time scale. We estimated associations between B-Cd quartiles and cardiovascular risk factors using three models. Model 1 included B-Cd in quartiles and gender. Model 2 (main model) also included other potential confounders, as shown in Table 1: smoking, waist circumference (a marker for obesity and a strong cardiovascular risk factor), low education, low physical activity, alcohol intake, serum triglycerides, HbA1c, and CRP. Model 3 additionally included other cardiovascular risk factors, not associated with B-Cd according to Table 1: post-menopausal status, hormonal replacement, treatment for hypertension, diabetes mellitus, lipid-lowering medication, diastolic blood pressure, LDL cholesterol, and HDL cholesterol.

We also investigated the effect of B-Cd as a continuous variable, using Generalized Additive Models with the mgcv package in version 3.0.2 of the R statistical software package (R Core Team 2013). We fitted a Poisson regression model with the effect of B-Cd represented using a smooth function. The model was identical to Model 2 but also included age (time scale in the Cox regression analysis). The smooth function was represented using a penalized regression spline with 3 degrees of freedom.

We examined possible effect modification for age group (>60 years), gender, smoking (never, former, or current), education (<9 years), waist circumference (>85 cm), hypertension (antihypertensive medication), and diabetes. This was performed for acute coronary events in the main model by stratification. For smoking and gender, we also tested possible effect modification for the other outcomes. For gender, effect modification was additionally assessed by inclusion of an interaction term in the model, tested by the Wald Chi-square.

We performed sensitivity analyses with the following alternative models: 1) restriction to participants with data for all covariates, ensuring the same number of participants in all three models (N=4045) 2) Ery-Cd instead of B-Cd, 3) inclusion of pack-years (categorized) in the model (when data were available, N=3938), 4) time on study as time scale (age as a covariate), 5) gender-specific quartiles for B-Cd, 6) inclusion of participants with an event prior to baseline, 7) inclusion of second-hand tobacco smoke (at home or at work) as an additional predictor (when data were available), 8) inclusion of alcohol as dichotomous variable (“high” intake defined as >30 grams/day in women and >40 grams/day in men, reported by 3.7% of participants), 9) inclusion of haematocrit in the models.

A two-tailed p-value <0.05 was considered statistically significant.

## **Results**

### **Baseline characteristics**

The mean estimated B-Cd level was 0.46 (median 0.26, geometric mean 0.31, 25<sup>th</sup> and 75<sup>th</sup> percentiles 0.17 and 0.50) µg/L. It was 0.47 µg/L in women and 0.45 µg/L in men. The mean Cd in erythrocytes was 1.12 µg/L (1.17 in women and 1.04 in men). Haematocrit ranged from 28 to 55% (mean 40%) in women and from 33 to 57% (mean 43%) in men. Cardiovascular risk factors stratified by quartiles of B-Cd are shown in Table 1. As expected, smoking was strongly associated with B-Cd, and there were only 6% never-smokers in the 4<sup>th</sup> B-Cd quartile compared to 62% in the 1<sup>st</sup> quartile. The 1<sup>st</sup> quartile had the lowest fraction of women. The 4<sup>th</sup> quartile had a higher prevalence of low education and low physical activity, and higher mean levels of

HbA1c and CRP. For other well-known risk factors, the differences between B-Cd quartiles were modest.

### **Cardiovascular morbidity and mortality**

From baseline to end of follow-up, there were 406 incident cases of coronary events. The analyses of coronary events were based on about 78500 person-years. When cases of coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) were also included, there were 527 incident major adverse cardiac events. There were 346 cases of stroke, 281 of which were ischemic. In total, 882 participants died during follow-up (analyses based on approximately 81400 person-years), and in 257 cases (29%), the cause of death was classified as cardiovascular. Numbers of first events (which were fewer than the total number of events) stratified by gender are shown in Supplemental Material, Table S1.

### **Associations between blood cadmium and cardiovascular morbidity and mortality**

The HRs for all cardiovascular endpoints were consistently higher for participants in the 4<sup>th</sup> quartile of B-Cd (0.50 – 5.1 µg/L, median 0.99 µg/L) compared to the 1<sup>st</sup> (0.02 – 0.17 µg/L, median 0.13 µg/L; Figure 1 and Table 2). The point estimate was approximately a doubled risk, irrespective of the model used.

The results based on quartiles (Table 2) shows that for several of the outcomes (e.g. acute coronary event and major adverse cardiac event) HRs >1 were found also in quartiles 2 and 3, while for stroke the increased risk was limited to the highest quartile. An estimate of the smoothed exposure-response relation for acute coronary event (Model 2) based on B-Cd as a

continuous variable is shown in Supplemental Material, Figure S2. For this outcome, the association seemed to be relatively linear up to B-Cd 1 µg/L and then flattened out.

The hazard ratios for acute coronary events were similar when stratified by age, sex, smoking, education, waist circumference, antihypertensive medication or diabetes (Table S2). Since smoking is the most important confounder, we examined cardiovascular outcomes in the 1915 never-smokers and found similar HRs in the 4<sup>th</sup> quartile as in the whole study population.

However, only 72 never-smokers had high B-Cd, so the number of events in this group is small (Table 3). Possible differences by gender also were studied for the other outcomes (Supplemental Material, Table S3). While associations were similar in women and men for acute coronary events, the HR for stroke in the highest versus lowest quartile was larger in women (HR = 2.8; 95% CI: 1.5, 5.4) than in men (HR = 1.5; 95% CI: 0.8, 2.8), and the p-value for interaction was 0.02.

### **Sensitivity analyses**

The following sensitivity analyses, performed for Model 2, all showed HRs very similar to those in Table 2:

- restriction to participants with data for all covariates (N=4045; Table S4).
- Ery-Cd instead of B-Cd as measure of cadmium burden (Table S5)
- inclusion of pack-years in the model (N=3938, Table S6)
- time on study as time scale instead of age (data not shown)
- gender-specific quartiles for B-Cd (data not shown)

- inclusion also of participants with an event prior to baseline (e.g. 355 acute coronary events instead of 328; data not shown)
- inclusion of second-hand tobacco smoke in the model (N=3564, data not shown)
- alcohol as a dichotomous variable (data not shown)
- inclusion of haematocrit in the B-Cd and Ery-Cd models (data not shown)

## Discussion

To our knowledge this study is the first to report results on incidence of cardiovascular disease in a Caucasian population with low to moderate cadmium exposure (25<sup>th</sup> and 75<sup>th</sup> percentiles of B-Cd 0.17 and 0.50 µg/L). These results suggest that the previous observation of elevated cardiovascular disease incidence at high cadmium exposure in Native Americans also may apply to general European and US populations with lower levels of exposure. We examined cardiovascular disease incidence in 4819 Swedish men and women over 17 years of follow-up. The incidence of most cardiovascular outcomes was doubled in the upper quartile of B-Cd (median 0.99 µg/L) at baseline compared with the lowest quartile (median 0.13 µg/L). Hazard ratios were 1.8 (95% confidence interval: 1.2 to 2.7) for acute coronary events and 1.9 (1.3 to 2.9) for stroke in a model taking relevant confounders into account. In never-smokers, the HRs were similar, although based on few events. Since the B-Cd levels in the upper quartile of the present study (median 0.99 µg/L) are common in many countries (Tellez-Plaza et al. 2012; Akerstrom et al. 2013a), our results suggest that cadmium may be an important cardiovascular risk factor.

## Comparison with previous studies

The only previous large study of incident cardiovascular disease is the Strong Heart Study in American Indians (Tellez-Plaza et al. 2013a), which reported HRs of 1.87 (95% CI 1.34, 2.60) for cardiovascular mortality, 1.33 (95% CI 1.05, 1.68) for incident coronary heart disease, and 1.87 for incident stroke (95% CI 1.22, 2.86) when the highest quartile of U-Cd (median 1.95  $\mu\text{g/g}$ ) was compared with the lowest (median 0.44  $\mu\text{g/g}$ ). The results were thus in agreement with the present study, although at higher levels of cadmium exposure. We did not have access to U-Cd in our cohort, but levels of U-Cd in  $\mu\text{g/g}$  creatinine are expected to be similar to (Fagerberg et al. 2012) or slightly lower than (Tellez-Plaza et al. 2012) levels of B-Cd in  $\mu\text{g/L}$ .

Other longitudinal studies are available for cardiovascular mortality (Tellez-Plaza et al. 2013b). The largest one was performed in the NHANES 1999-2004 population with a follow-up time of five years; 9000 participants showed a geometric mean B-Cd of 0.44  $\mu\text{g/L}$  (Tellez-Plaza et al. 2012), only slightly higher than in our cohort (GM 0.31  $\mu\text{g/L}$ ). In that study, the hazard ratio for cardiovascular mortality was 1.69 (95% confidence interval: 1.03 to 2.77), comparing the upper quintile of B-Cd ( $>0.8 \mu\text{g}$ ) with the lowest ( $<0.22 \mu\text{g/L}$ ). Results were similar for U-Cd. Thus our results for cardiovascular mortality (hazard ratio 1.9, 95% CI 1.1, 3.2 in Model 2, Table 2) when comparing the upper quartile ( $>0.5 \mu\text{g/L}$ ) with the lowest ( $<0.17 \mu\text{g/L}$ ) are in agreement with those of the NHANES study.

In a Japanese study of people living in a cadmium-polluted area ( $N=3119$ ), the hazard ratio for cardiovascular mortality was 1.8 (95% confidence interval: 1.0 to 3.1) for men and 2.4 (95% confidence interval: 1.1 to 5.1) for women, comparing participants with U-Cd $>10 \mu\text{g/g}$  creatinine



with those having  $U\text{-Cd} < 3.0 \mu\text{g/g}$  creatinine (Li et al. 2011). However, the analyses did not include smoking or other potential confounders.

In a Belgian study, cardiovascular mortality was followed up for 20 years in 900 people with a geometric mean  $B\text{-Cd}$  of  $1.1 \mu\text{g/L}$ . The HR for cardiovascular mortality (88 cases) was 1.20 (95% confidence interval: 0.90 to 1.60) at a doubling of  $B\text{-Cd}$  (Nawrot et al. 2008).

These studies, and the present one, relied on biomarkers of cadmium exposure. There are, however, two recent reports on prospective cohort studies finding no association between cardiovascular disease and dietary cadmium intake during the past year, as estimated from food frequency questionnaires. One of the studies was performed in about 33,000 women (Julin et al. 2013a), and the other one in about 37,000 men (Julin et al. 2013a). This inconsistency may have several explanations. Firstly, the estimated cadmium intake may suffer from errors, resulting in non-differential misclassifications which attenuate a true relationship, as discussed by the authors. In addition, dietary intake estimates do not take into account differences in absorption of dietary cadmium due to, for example, varying iron stores. In fact, the Pearson correlation between estimated dietary intake in the food frequency studies and  $U\text{-Cd}$  was only 0.1. Moreover, the exposure contrast in these studies was very limited.

In Sweden, the bulk of the dietary cadmium is accounted for by cereals, potatoes, and vegetables, although higher levels are found in liver, kidney and certain shellfish (Julin et al. 2013b).

### **Potential mechanisms**

There are several potential mechanisms that could explain the association between  $B\text{-Cd}$  and cardiovascular disease found in the present study, in the NHANES study, and in the Strong Heart

Study. One major hypothesis is that cadmium increases the risk of atherosclerosis (Tellez-Plaza et al. 2013b). This is supported by studies showing associations between B-Cd and the prevalence, size, and growth of atherosclerotic plaques in Swedish women (Fagerberg et al. 2012) and in the Malmö Diet and Cancer Study (Fagerberg et al. 2015), studies of cadmium and peripheral artery disease (Fagerberg et al. 2013; Tellez-Plaza et al. 2010), and a study of cadmium in plaques (Bergström et al. 2015).

There is also experimental support for a proatherogenic impact of cadmium. Cadmium exposure was associated with atherosclerosis in the aorta in ApoE knockout mice (Knoflach et al. 2011). In vitro studies have shown DNA damage, increased permeability of vascular endothelium, inhibition of endothelial cell proliferation, and apoptosis (Knoflach et al. 2011). Cadmium exposure may affect vascular endothelium via cellular adhesion molecules or via protein kinase signalling (Prozialeck et al. 2008). There are also experimental data indicating that cadmium exposure may have a direct toxic effect on the myocardium (Ozturk et al. 2009; Turdi et al. 2013).

### **Confounding by smoking**

The point estimates of the HRs were similar in never-smokers as in the combined group of ever- and never-smokers with smoking included in the models. This is important, since confounding by smoking is always an issue in cardiovascular epidemiology. Adjustment for smoking in the statistical models may be insufficient, as self-reported smoking levels may be inaccurate. Moreover, the cadmium content in cigarette brands, and the amount of smoke inhaled may differ between individuals. Such differences may be captured by biomarkers, but not by self-reported

data. The meta-analysis by Tellez-Plaza et al. found that the risk estimate for any cardiovascular disease was similar in never-smokers compared to the overall combined risk estimate, but the authors noted that more studies among never-smokers were called for (Tellez-Plaza et al. 2013b).

### **Strengths and limitations**

The strengths of the present prospective study are the long follow-up period (17 – 20 years), the fact that very few participants were lost to follow-up (30 who emigrated), and the high validity of the Swedish national death and hospital registers (Hammar et al. 2001; Kahn et al. 2004; Sarno et al. 2013). For example the sensitivity of the hospital discharge registers was 94-96% (Hammar et al. 2001). Detailed data were available on potential confounders at baseline, but we could not account for changes during follow-up. The fact that quantitative smoking data were of available for some of the ex-smokers is a limitation. Another limitation is that we had no access to urinary cadmium. B-Cd reflects the body burden and long term exposure as long as dietary and smoking habits are stable, but after smoking cessation, change in dietary habits, or change in iron status, B-Cd changes faster than U-Cd (Nordberg et al. 2015). On the other hand, U-Cd may have substantial within-person variability, due to variation in renal physiology (Akerstrom et al. 2013b). The age of participants at baseline was 46-67 years. B-Cd and U-Cd normally increases with age, and in the younger participants it may have been somewhat higher in the end of the observation period than at baseline. Finally, cadmium was not determined in whole blood, but calculated from haematocrit and Cd in erythrocytes. It is not known whether Cd in whole blood or Cd in erythrocytes best reflects the body burden of Cd. High haematocrit has been reported to be a risk factor for cardiovascular disease, but we found no such impact when it was added to our models.

## **Conclusion**

In conclusion, the present study suggests that cadmium exposure is an important risk factor for cardiovascular disease. Since dietary exposure is widespread, preventive strategies in never-smokers are needed on a societal level, such as limiting industrial release of cadmium to the environment where it ends up in cultivated land and crops. Moreover, the findings underline continuous efforts to against tobacco smoking.

## References

- Akerstrom M, Barregard L, Lundh T, Sallsten G. 2013a. The relationship between cadmium in kidney and cadmium in urine and blood in an environmentally exposed population. *Toxicol Appl Pharmacol* 268:286-93.
- Akerstrom M, Sallsten G, Lundh T, Barregard L. 2013b. Associations between urinary excretion of cadmium and proteins in a non-smoking population: Renal toxicity or normal physiology? *Environ Health Perspect* 121:187–91.
- Åkesson A, Barregard L, Bergdahl IA, Nordberg GF, Nordberg M, Skerfving S. 2014. Non-Renal Effects and the Risk Assessment of Environmental Cadmium Exposure. *Environ Health Perspect* 122:431–8.
- Almenara CC, Broseghini-Filho GB, Vescovi MV, Angeli JK, Faria Tde O, Stefanon I, et al. 2013. Chronic cadmium treatment promotes oxidative stress and endothelial damage in isolated rat aorta. *PLoS One* 12:8.
- Berglund G, Elmståhl S, Janzon L, Larsson SA. 1993. The Malmö Diet and Cancer Study. Design and feasibility. *J Intern Med* 223:45–51.
- Bergström G, Fagerberg B, Sallsten G, Lundh T, Barregard L. 2015. Is cadmium exposure associated with the burden, vulnerability and rupture of human atherosclerotic plaques? *PLoS One* Mar 27;10(3):e0121240.

Fagerberg B, Barregard L, Sallsten G, Forsgard N, Östling G, Persson M, et al. 2015. Cadmium exposure and atherosclerotic carotid plaques – Results from the Malmö Diet and Cancer Study. *Environ Res* 136:67-74.

Fagerberg B, Bergström G, Borén J, Barregard L. 2012. Cadmium exposure is accompanied by increased prevalence and future growth of atherosclerotic plaques in 64-year-old women. *J Intern Med* 272:601–10.

Fagerberg B, Bergström G, Borén J, Barregard L. 2013. Cadmium exposure, intercellular adhesion molecule-1 and peripheral artery disease: a cohort and an experimental study. *BMJ Open* 3: e002489.

Hammar N, Alfredsson L, Rosén M, Spetz CL, Kahan T, Ysberg AS. 2001. A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. *Int J Epidemiol* 30,Suppl 1: S30–4.

Hedblad B, Nilsson P, Janzon L, Berglund G. 2000. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmö, Sweden. *Diabet Med* 17:299–307.

IARC International Agency for Research on Cancer. 2012. Cadmium and cadmium compounds. In *Arsenic, metals, fibres, and dusts*. Vol.100c. IARC Monographs. WHO Press, Geneva. Available at: <http://monographs.iarc.fr/ENG/Monographs/vol100C/mono100C-8.pdf>

Julin B, Bergkvist C, Wolk A, Åkesson A. 2013a. Cadmium in diet and risk of cardiovascular disease in women. *Epidemiology* 24:880–5.

Julin B, Wolk A, Thomas LD, Akesson A. 2013b. Exposure to cadmium from food and risk of cardiovascular disease in men: A population-based prospective cohort study. *Eur J Epidemiol* 28:837–40.

Khan FA, Zia E, Janzon L, Engstrom G. 2004. Incidence of stroke and stroke subtypes in Malmö, Sweden, 1990-2000: marked differences between groups defined by birth country. *Stroke* 35:2054–8.

Knoflach M, Messner B, Shen YH, Frotschnig S, Liu G, Pfaller K, et al. 2011. Non-toxic cadmium concentrations induce vascular inflammation and promote atherosclerosis. *Circ J* 75:2491–5.

Li C, Aronsson CA, Hedblad B, Gullberg B, Wirfält E, Berglund G. 2009. Ability of physical activity measurements to assess health-related risks. *Eur J Clin Nutr* 63:1448–51.

Li Q, Nishijo M, Nakagawa H, Morikawa Y, Sakurai M, Kido T, et al. 2011. Relationship between urinary cadmium and mortality in habitants of a cadmium-polluted area: A 22-year follow-up study in Japan. *Chin Med J* 124:3504–9.

Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C et al. 2011. External review and validation of the Swedish national inpatient register. *BMC Public Health* Jun 9;11:450.

Menke A, Muntner P, Silbergeld EK, Platz EA, Guallar E. 2009. Cadmium levels in urine and mortality among U.S. adults. *Environ Health Perspect* 117:190–6.

Messner B, Knoflach M, Seubert A, Ritsch A, Pfaller K, Henderson B, et al. 2009. Cadmium is a novel and independent risk factor for early atherosclerosis mechanisms and in vivo relevance.

Arterioscler Thromb Vasc Biol 29:1392–8.

Nawrot TS, Van Hecke E, Thijs L, Richart T, Kuznetsova T, Jin Y, et al. 2008. Cadmium-related mortality and long-term secular trends in the cadmium body burden of an environmentally exposed population. Environ Health Perspect 116:1620–8.

Nordberg GF, Nogawa K, Nordberg M. Cadmium. 20015. In: Nordberg GF, Fowler GF, Nordberg M (Eds). Handbook on the Toxicology of Metals. Amsterdam: Elsevier, pp 667–716.

Ozturk IM, Buyukakilli B, Balli E, Cimen B, Gunes S, Erdogan S. 2009. Determination of acute and chronic effects of cadmium on the cardiovascular system of rats. Toxicol Mech Methods 19:308–17.

Prozialeck WC, Edwards JR, Nebert DW, Woods JM, Barchowsky A, Atchison WD. 2008. The vascular system as a target of metal toxicity. Toxicol Sci 102:207–18.

R Core Team. 2013. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available: <http://www.R-project.org/>. [Accessed Nov 2014].

Sarno G, Lagerqvist B, Carlsson J, Olivecrona G, Nilsson J, Calais F, et al. 2013. Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Int J Cardiol 167:146–50.



Tellez-Plaza M, Guallar E, Howard BV, Umans JG, Francesconi KA, Goessler W, et al. 2013a. Cadmium exposure and incident cardiovascular disease. *Epidemiology* 24:421–9.

Tellez-Plaza M, Jones MR, Dominguez-Lucas A, Guallar E, Navas-Acien A. 2013b. Cadmium exposure and clinical cardiovascular disease: A systematic review. *Curr Atheroscler Rep* 15:356.

Tellez-Plaza M, Navas-Acien A, Crainiceanu CM, Sharrett AR, Guallar E. 2010. Cadmium and peripheral arterial disease: Sex differences in the 1999–2004 US national health and nutrition examination survey. *Am J Epidemiol* 172:671–81.

Tellez-Plaza M, Navas-Acien A, Menke A, Crainiceanu CM, Pastor-Barriuso R, Guallar E. 2012. Cadmium exposure and all-cause and cardiovascular mortality in the U.S. general population. *Environ Health Perspect* 120:1017–22.

Turdi S, Sun W, Tan Y, Yang X, Cai L, Ren J. 2013. Inhibition of DNA methylation attenuates low-dose cadmium-induced cardiac contractile and intracellular Ca(2+) anomalies. *Clin Exp Pharmacol Physiol* 40:706–12.

World Health Organization. 2011. Evaluation of certain food additives and contaminants. Seventy-third report of the Joint FAO/WHO Expert Committee on Food Additives. Geneva. Available at: <http://www.inchem.org/documents/jecfa/jecmono/v64je01.pdf>

**Table 1.** Characteristics of the study cohort at baseline by quartiles of blood cadmium.

Variable <sup>a)</sup>	All	Quartiles of blood cadmium				P-value Q4 vs. Q1
Blood cadmium quartile limits ( $\mu\text{g/L}$ ) <sup>b)</sup>		<0.17	0.17 – 0.259	0.26 – 0.499	0.50 – 5.1	
Number of participants	4819	1205	1205	1205	1204	
Blood cadmium, mean (median)	0.46 (0.26)	0.13 (0.13)	0.21 (0.21)	0.35 (0.34)	1.2 (0.99)	
Age (years), mean (SE)	57 (0.1)	57 (0.2)	58 (0.2)	58 (0.2)	57 (0.2)	0.65
Women, n (%)	2861 (59)	597 (50)	755 (63)	796 (66)	713 (59)	<0.001
Never smoker, n (%)	1915 (40)	752 (62)	619 (51)	472 (39)	72 (6.0)	<0.001
Ex-smoker, n (%)	1628 (34)	409 (34)	519 (43)	547 (45)	153 (13)	<0.001
Current smoker, n (%)	1276 (26)	44 (3.7)	67 (5.6)	186 (15)	979 (81)	<0.001
Pack-years, GM (GSD) <sup>c)</sup>	13 (3.3)	5.4 (3.9)	7.3 (3.8)	9.7 (3.2)	21 (2.3)	<0.001
Missing data for pack-years, n	681	7	272	299	103	
Second-hand smoke, n (%)	3967 (73)	628 (65)	673 (68)	728 (73)	848 (84)	<0.001
BMI ( $\text{kg/m}^2$ ), mean (SE)	26 (0.1)	26 (0.1)	26 (0.1)	26 (0.1)	25 (0.1)	<0.001
Waist (cm), GM (GSD)	83 (1.2)	84 (1.2)	82 (1.2)	82 (1.2)	82 (1.2)	<0.001
Low education level, n (%)	2223 (46)	500 (42)	528 (44)	562 (47)	633 (53)	<0.001
Low physical activity, n (%)	1115 (24)	251 (21)	268 (23)	281 (24)	315 (27)	0.001
Post-menopausal status, n (%) <sup>d)</sup>	2113 (74)	443 (74)	560 (74)	590 (74)	520 (73)	0.66
Hormonal replacement, n (%) <sup>d)</sup>	502 (20)	112 (22)	129 (19)	142 (20)	119 (18)	0.12
Alcohol intake (g/day), mean (SE)	10 (0.2)	10 (0.3)	10 (0.3)	10 (0.3)	11 (0.4)	0.05
High alcohol intake, n (%)	177 (4)	45 (4)	34 (3)	34 (3)	64 (5)	0.06
Treatment for hypertension, n (%)	797 (17)	180 (15)	217 (18)	223 (19)	177 (15)	0.91
Diabetes mellitus, n (%)	392 (8.2)	121 (10)	92 (7.6)	83 (6.9)	96 (8.0)	0.09
Lipid lowering treatment, n (%)	117 (2.4)	28 (2.3)	23 (1.9)	38 (3.1)	28 (2.3)	1.0
Systolic blood pressure (mm Hg), mean (SE)	141 (0.3)	141 (0.5)	141 (0.5)	142 (0.5)	140 (0.6)	0.35
Diastolic blood pressure (mm Hg), mean (SE)	87 (0.1)	87 (0.3)	87 (0.3)	87 (0.3)	87 (0.3)	0.17
LDL cholesterol (mmol/L), mean (SE)	4.2 (0.01)	4.2 (0.03)	4.2 (0.03)	4.1 (0.03)	4.2 (0.03)	0.09

HDL cholesterol (mmol/L), mean (SE)	1.4 (0.01)	1.3 (0.01)	1.4 (0.01)	1.4 (0.01)	1.3 (0.01)	0.89
Triglycerides (mmol/L), GM (GSD)	1.2 (1.6)	1.2 (1.6)	1.2 (1.6)	1.2 (1.6)	1.3 (1.6)	0.03
HbA1c (mmol/mol), GM (GSD)	4.8 (1.1)	4.8 (1.1)	4.8 (1.1)	4.8 (1.1)	5.0 (1.1)	<0.001
hsCRP (mg/L), GM (GSD)	1.4 (2.9)	1.2 (2.8)	1.2 (2.8)	1.4 (2.7)	1.8 (3.0)	<0.001
Haematocrit (%), mean (SE)	41 (0.05)	41 (0.1)	41 (0.1)	41 (0.1)	42 (0.1)	<0.001

**a)** Missing data: BMI 4, Waist 4, Education 12, Physical activity 118, Menopausal status 8, Hormonal replacement 317, Alcohol 23, Lipid lowering treatment 136, HDL 69, HbA1c24, CRP 217. The missing data were relatively evenly distributed by blood cadmium quartiles.

**b)** 1 µg/L = 9 nmol/L.

**c)** Means refer to smoking or ex-smoking participants with available data. Data are available for 95% of current smokers and 50% of ex-smokers.

**d)** Among women.

**Table 2.** Hazard ratios (95% confidence intervals) for incident first cardiovascular disease event by quartiles of cadmium concentration in blood (time scale=age).

<b>Outcome and Model</b>	<b>Quartiles of blood cadmium</b>			
	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>
<b>Acute coronary event <sup>a)</sup></b>				
Sample size (N=4745)	1195	1191	1181	1178
Number of events (N=377)	80	81	88	128
Incidence/1000 person-years	4.0	4.0	4.1	6.9
Model 1 (377 events)	1.0	1.1 (0.8 , 1.4)	1.2 (0.9 , 1.6)	2.0 (1.5 , 2.7)
Model 2 (328 events)	1.0	1.1 (0.8 , 1.6)	1.3 (0.9 , 1.8)	1.8 (1.2 , 2.7)
Model 3 (306 events)	1.0	1.0 (0.7 , 1.4)	1.2 (0.8 , 1.6)	1.9 (1.2 , 2.9)
<b>Acute myocardial infarction</b>				
Sample size (N=4745)	1195	1191	1181	1178
Number of events (N=344)	75	77	79	113
Incidence/1000 person-years	3.7	3.8	4.0	6.1
Model 1 (344 events)	1.0	1.1 (0.8 , 1.5)	1.1 (0.8 , 1.6)	1.9 (1.4 , 2.5)
Model 2 (305 events)	1.0	1.2 (0.8 , 1.6)	1.3 (0.9 , 1.8)	1.7 (1.1 , 2.7)
Model 3 (283 events)	1.0	1.0 (0.7 , 1.5)	1.1 (0.8 , 1.6)	1.8 (1.2 , 2.8)
<b>Major adverse cardiac event <sup>b)</sup></b>				
Sample size (N=4726)	1191	1187	1174	1174
Number of events (N=479)	96	193	122	158
Incidence/1000 person-years	4.8	5.2	6.3	8.0
Model 1 (479 events)	1.0	1.2 (0.9 , 1.5)	1.4 (1.1 , 1.9)	2.1 (1.6 , 2.7)
Model 2 (422 events)	1.0	1.2 (0.9 , 1.7)	1.5 (1.1 , 2.0)	1.9 (1.3 , 2.7)
Model 3 (394 events)	1.0	1.1 (0.9 , 1.5)	1.4 (1.0 , 1.9)	1.9 (1.3 , 2.8)
<b>Any stroke</b>				
Sample size (N=4583)	1201	1196	1195	1191
Number of events (N=336)	76	71	74	115
Incidence/1000 person-years	3.8	3.5	3.7	6.2
Model 1 (336 events)	1.0	0.9 (0.6 , 1.2)	0.9 (0.7 , 1.3)	1.8 (1.3 , 2.4)
Model 2 (294 events)	1.0	0.9 (0.6 , 1.3)	1.0 (0.7 , 1.4)	1.9 (1.3 , 2.9)
Model 3 (271 events)	1.0	0.8 (0.6 , 1.2)	0.9 (0.7 , 1.4)	2.1 (1.3 , 3.2)
<b>Ischemic stroke</b>				
Sample size (N=4796)	1202	1201	1196	1197
Number of events (N=278)	63	58	59	98
Incidence/1000 person-years	3.1	2.9	2.9	5.2
Model 1 (278 events)	1.0	0.9 (0.6 , 1.2)	0.9 (0.6 , 1.3)	1.9 (1.3 , 2.5)
Model 2 (240 events)	1.0	0.9 (0.6 , 1.3)	0.9 (0.6 , 1.4)	1.9 (1.2 , 3.1)
Model 3 (224 events)	1.0	0.8 (0.6 , 1.2)	0.9 (0.6 , 1.3)	2.1 (1.3 , 3.3)
<b>All cause mortality</b>				
Sample size (N=4819)	1205	1205	1205	1204
Number of events (N=882)	169	189	205	319
Mortality/1000 person-years	8.2	9.1	10.0	16.4
Model 1 (882 events)	1.0	1.1 (0.9 , 1.3)	1.2 (1.0 , 1.4)	2.3 (1.9 , 2.7)
Model 2 (771 events)	1.0	1.0 (0.8 , 1.2)	1.1 (0.8 , 1.3)	1.6 (1.2 , 2.0)
Model 3 (718 events)	1.0	1.0 (0.8 , 1.3)	1.0 (0.8 , 1.3)	1.6 (1.3 , 2.2)

<b>Cardiovascular mortality</b>				
Sample size (N=4819)	1205	1205	1205	1204
Number of events (N=257)	45	57	66	89
Mortality/1000 person-years	2.2	2.7	3.2	4.6
Model 1 (257 events)	1.0	1.2 (0.8 , 1.8)	1.4 (1.0 , 2.1)	2.4 (1.7 , 3.5)
Model 2 (215 events)	1.0	1.2 (0.8 , 1.9)	1.4 (0.9 , 2.1)	1.9 (1.1 , 3.2)
Model 3 (206 events)	1.0	1.2 (0.8 , 1.9)	1.3 (0.9 , 2.1)	1.9 (1.1 , 3.2)

Model 1 was adjusted for gender. Model 2 was as Model 1 and also adjusted for the other potential confounders in Table 1: smoking, waist circumference, low education, low physical activity, alcohol intake, serum triglycerides, HbA1c, and CRP. Model 3 was as Model 2 and also adjusted for additional cardiovascular risk factors: post-menopausal status, hormonal replacement, treatment for hypertension, diabetes mellitus, lipid-lowering medication, diastolic blood pressure, LDL cholesterol, and HDL cholesterol. Denominators are not identical for all outcomes since participants with events before baseline were excluded.

**a)** ICD9: 410, 412, or 414 or ICD10: I21, I22, I23 or I25.

**b)** Acute MI, death in IHD, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI).

**Table 3.** Hazard ratios for incident first cardiovascular disease by quartiles of cadmium concentration in blood (time scale=age) *in never-smokers*. Model 2 is adjusted for the potential confounders in Table 1: gender, smoking, waist circumference, low education, low physical activity, alcohol intake, serum triglycerides, HbA1c, and CRP.

<b>Outcome</b>	<b>Quartiles of blood cadmium</b>			
<b>Acute coronary event <sup>a)</sup></b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>
Sample size (N=1782)	702	578	441	61
Number of events (N=111)	47	31	26	7
HR (95% CI)	1.0	0.9 (0.6 , 1.5)	1.0 (0.6 , 1.6)	2.3 (1.0 , 5.1)
<b>Acute myocardial infarction</b>				
Sample size (N=1782)	702	578	441	61
Number of events (N=106)	44	31	24	7
HR (95% CI)	1.0	1.0 (0.6 , 1.5)	1.0 (0.6 , 1.6)	2.4 (1.1 , 5.4)
<b>Major adverse cardiac event<sup>b</sup></b>				
Sample size (N=1777)	700	576	440	61
Number of events (N=136)	57	39	32	8
HR (95% CI)	1.0	1.0 (0.7 , 1.5)	1.1 (0.7 , 1.7)	2.2 (1.0 , 4.6)
<b>Any stroke</b>				
Sample size (N=1785)	703	579	442	61
Number of events (N=111)	41	32	31	7
HR (95% CI)	1.0	1.0 (0.6 , 1.6)	1.2 (0.7 , 2.0)	2.2 (1.0 , 4.8)
<b>Ischemic stroke</b>				
Sample size (N=1789)	704	581	443	61
Number of events (N=85)	32	25	22	6
HR (95% CI)	1.0	1.0 (0.6 , 1.7)	1.1 (0.6 , 2.0)	2.5 (1.0 , 6.0)
<b>All-cause mortality</b>				
Sample size (N=1793)	705	582	445	61
Number of events (N=238)	93	75	59	11
HR (95% CI)	1.0	1.0 (0.7 , 1.3)	1.0 (0.7 , 1.3)	1.3 (0.7 , 2.4)
<b>Cardiovascular mortality</b>				
Sample size (N=1793)	705	582	445	61
Number of events (N=69)	22	26	16	5
HR (95% CI)	1.0	1.4 (0.8 , 2.6)	1.1 (0.6 , 2.2)	2.6 (1.0 , 6.9)

**a)** ICD9: 410, 412, or 414 or ICD10: I21, I22, I23 or I25.

**b)** Acute MI, death in IHD, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI). Some individuals with CABG or PCI also developed AMI or died in IHD.

## Figure Legends

**Figure 1.** Hazard ratios and 95% confidence intervals for acute coronary event (ACE = acute myocardial infarction, or death in ischemic heart disease), major cardiac events (ACE, or coronary artery by-pass graft, or percutaneous coronary intervention), stroke, and cardiovascular mortality by quartiles of cadmium concentration in blood (white = quartile 1, black = quartile 4). The models were adjusted for age (time scale), gender, smoking, waist circumference, low education, low physical activity, alcohol intake, serum triglycerides, HbA1c, and C-reactive protein. For other models, see Table 2.

Figure 1.

